The development of colorectal cancer (CRC) is a multi-step process, called the polyp to cancer sequence, resulting from the accumulation of genomic alterations and epigenetic alterations in colon epithelial cells. These epigenetic alterations include the aberrant methylation of the 5'promoter region of genes with CpG islands, which can silence the expression of tumor suppressor genes. The accumulation of aberrantly methylated genes begins at the pre-cancer phase of CRC formation and is common in CRC, affecting thousands of genes, and resulting in a variety of different tumor promoting biological effects on the CRCs. An unanswered question is how the methylated genes vary between the known CRC molecular subgroups, Chromosomal Unstable (CIN), Microsatellite Unstable (MSI), and CpG Island Methylator Phenotype (CIMP) tumors. Thus, we propose to create a Research Team under the guidance of two PIs, William Grady and Sanford Markowitz, to lead an EDRN Biomarker Developmental Lab to discover novel methylated genes that can be used as early detection markers and predictive markers using cutting-edge and complementary approaches, HumanMethylation27 DNA Analysis Beadchip (lllumina Infinium platform), and deep sequencing of captured NaHSO3 treated DNA (Agilent and Solexa). These approaches will take advantage of the developed expertise of the Grady lab and of the Markowitz lab, respectively, and have the potential to identify a panel of complementary biomarkers for the early detection of colorectal neoplasms and for enhancing the care of early stage CRC. We propose the following Specific Aims:
Aim 1) To develop and validate epigenetic signatures of colon adenomas and early stage non-metastatic colon cancers.
Aim 2) To perform a comprehensive epigenomic characterization of colorectal cancer molecular subtypes. 2a) To develop differential methylation profiles between CIMP and nonCIMP CRCs. 2b) To develop differential methylation profiles between CIN vs. MSI CRCs.
Aim 3) To identify and characterize biologically relevant novel methylation targets in colorectal cancer.
|Shiovitz, Stacey; Bertagnolli, Monica M; Renfro, Lindsay A et al. (2014) CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147:637-45|
|Yu, M; Trobridge, P; Wang, Y et al. (2014) Inactivation of TGF-* signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene 33:1538-47|
|Luo, Yanxin; Wong, Chao-Jen; Kaz, Andrew M et al. (2014) Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 147:418-29.e8|
|Fink, Stephen P; Yamauchi, Mai; Nishihara, Reiko et al. (2014) Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 6:233re2|
|Abrams, Julian A; Appelman, Henry D; Beer, David G et al. (2014) Barrett's Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. Gastroenterology 146:1586-90|
|Kaz, Andrew M; Grady, William M (2014) Epigenetic biomarkers in esophageal cancer. Cancer Lett 342:193-9|
|Grady, William M; Pritchard, Colin C (2014) Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol 42:124-39|
|Khatayevich, Dmitriy; Page, Tamon; Gresswell, Carolyn et al. (2014) Selective detection of target proteins by peptide-enabled graphene biosensor. Small 10:1505-13, 1504|
|Kaz, Andrew M; Wong, Chao-Jen; Dzieciatkowski, Slavomir et al. (2014) Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics 9:492-502|
|Luo, Y; Tsuchiya, K D; Il Park, D et al. (2013) RET is a potential tumor suppressor gene in colorectal cancer. Oncogene 32:2037-47|
Showing the most recent 10 out of 19 publications